共 50 条
- [21] CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablationANNALS OF ONCOLOGY, 2018, 29Exposito, M. J. JimenezAkce, M.Montero Alvarez, J. L.Assenat, E.Balart, L. A.Baron, A. D.Decaens, T.Heurgue-Berlot, A.Martin, A. O.Paik, S. W.Poulart, V.Sehbai, A. S.Takemura, N.Yoon, J-H.
- [22] CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablationANNALS OF ONCOLOGY, 2018, 29Exposito, M. J. JimenezAkce, M.Alvarez, J. L. M.Assenat, E.Balart, L. A.Baron, A. D.Decaens, T.Heurgue-Berlot, A.Martin, A. O.Paik, S. W.Poulart, V.Sehbai, A. S.Shimada, M.Takemura, N.Yoon, J-H.
- [23] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 studyLIVER CANCER, 2024, 13 (04) : 401 - 412Kudo, MasatoshiTsuchiya, KaoruShao, Yu-YunFinn, Richard S.Galle, Peter R.Ducreux, MichelCheng, Ann-LiiYamashita, TatsuyaKoga, HironoriTake, RyosukeYamada, KyokoAsakawa, TakashiNakagawa, YukiIkeda, Masafumi
- [24] IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III StudyLIVER CANCER, 2023, 12 (03) : 238 - 250Kudo, MasatoshiFinn, Richard S. S.Galle, Peter R. R.Zhu, Andrew X. X.Ducreux, MichelCheng, Ann-LiiIkeda, MasafumiTsuchiya, KaoruAoki, Ken-ichiJia, JingLencioni, Riccardo
- [25] Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular CarcinomaJOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 1065 - 1079Kaseb, Ahmed O.Guan, YinghuiYavuz, Betul GokAbbas, Alexander R.Lu, ShanHasanov, ElshadToh, Han ChongVerret, WendyWang, Yulei
- [26] IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY, 2021, 74 : 646A - 647AZhu, Andrew X.Finn, RichardDucreux, MichelHu, YouyouSommer, NicolasVerret, WendyKulik, Laura M.Galle, Peter R.
- [27] A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Uzzo, RobertBex, AxelRini, Brian I.Albiges, LaurenceSuarez, CristinaDonaldson, FrankAsakawa, TakashiSchiff, ChristinaPal, Sumanta K.
- [28] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Chen, YiwenShen, YanZhang, MinWu, JianGao, ShunliangQue, RishengYu, JunTang, XiaofengBai, XueliLiang, Tingbo
- [29] Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2023, 149 : 10505 - 10518Xu FengGuo-Ying FengJie TaoYu-Pei AoXin-Hua WuShi-Guai QiZheng-Rong Shi
- [30] Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinomaJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10505 - 10518Feng, XuFeng, Guo-YingTao, JieAo, Yu-PeiWu, Xin-HuaQi, Shi-GuaiShi, Zheng-Rong